Dr Reddy’s launches Versavo (bevacizumab) in the UK
It is indicated for the treatment of several types of cancers
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
bevacizumab
India pharma giants and global big pharma join forces for NMEs commercialisation in India:…
The focus is on introducing new molecular entities (NMEs) into India, with both parties contributing to accelerate…
Biocon Biologics Partners with Sandoz Australia for Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Enzene Biosciences launches Ranibizumab to treat neovascular AMD
Ranibizumab biosimilar is the company’s seventh biosimilar
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of…
The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per…
Sandoz enters into agreement with Bio-Thera Solutions for Bevacizumab
Bevacizumab is a recombinant humanised monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key…
US FDA accepts Amneal’s Biologics License Application for Bevacizumab
Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA
Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab
Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell…
Biocon Biologics and Viatris get CHMP Nod for Abevmy
Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth
USFDA defers action on BLA for Avastin biosimilar, notifies Biocon Biologics, Mylan
To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the…